Keymed Biosciences Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Bo Chen

Algemeen directeur

CN¥4.8m

Totale compensatie

Percentage CEO-salaris	95.9%
Dienstverband CEO	3.6yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	4.2yrs
Gemiddelde ambtstermijn bestuur	3.7yrs

Recente managementupdates

Recent updates

Health Check: How Prudently Does Keymed Biosciences (HKG:2162) Use Debt?

Oct 21

There's Reason For Concern Over Keymed Biosciences Inc.'s (HKG:2162) Massive 28% Price Jump

May 13

News Flash: 10 Analysts Think Keymed Biosciences Inc. (HKG:2162) Earnings Are Under Threat

Apr 03

Keymed Biosciences Inc. (HKG:2162) Just Reported And Analysts Have Been Cutting Their Estimates

Mar 31

A Look At The Intrinsic Value Of Keymed Biosciences Inc. (HKG:2162)

Nov 13

Analysts Just Made A Noticeable Upgrade To Their Keymed Biosciences Inc. (HKG:2162) Forecasts

Sep 03

Broker Revenue Forecasts For Keymed Biosciences Inc. (HKG:2162) Are Surging Higher

Mar 21

Companies Like Keymed Biosciences (HKG:2162) Are In A Position To Invest In Growth

Jun 27

Analyse CEO-vergoeding

Hoe is Bo Chen's beloning veranderd ten opzichte van Keymed Biosciences's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-CN¥743m
Mar 31 2024	n/a	n/a	-CN¥551m
Dec 31 2023	CN¥5m	CN¥5m	-CN¥359m
Sep 30 2023	n/a	n/a	-CN¥313m
Jun 30 2023	n/a	n/a	-CN¥267m
Mar 31 2023	n/a	n/a	-CN¥287m
Dec 31 2022	CN¥4m	CN¥4m	-CN¥308m
Sep 30 2022	n/a	n/a	-CN¥281m
Jun 30 2022	n/a	n/a	-CN¥253m
Mar 31 2022	n/a	n/a	-CN¥2b
Dec 31 2021	CN¥4m	CN¥4m	-CN¥4b
Sep 30 2021	n/a	n/a	-CN¥4b
Jun 30 2021	n/a	n/a	-CN¥4b
Mar 31 2021	n/a	n/a	-CN¥3b
Dec 31 2020	CN¥231k	CN¥227k	-CN¥819m
Dec 31 2019	CN¥188k	CN¥183k	-CN¥168m

Compensatie versus markt: De totale vergoeding ($USD 667.01K ) Bo } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 478.03K ).

Compensatie versus inkomsten: De vergoeding van Bo is gestegen terwijl het bedrijf verliesgevend is.

CEO

Bo Chen (49 yo)

3.6yrs

Tenure

CN¥4,788,000

Compensatie

Dr. Bo Chen has been executive Director, chairman of Board and chief executive officer at Keymed Biosciences Inc. since April 03, 2021 and served as Director since April 23, 2018 until April 03, 2021. Dr....

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Bo Chen	Executive Chairman & CEO	3.6yrs	CN¥4.79m	geen gegevens
Gang Xu	Senior VP & Executive Director	3.6yrs	CN¥1.61m	geen gegevens
Changyun Wang	Senior VP & Executive Director	6.5yrs	CN¥2.81m	geen gegevens
Qi Chen	Senior VP & Non Executive Director	6.7yrs	CN¥178.00k	geen gegevens
Yanrong Zhang	CFO, VP & Joint Company Secretary	4.2yrs	geen gegevens	geen gegevens
Qian Jia	Senior Vice President	6.7yrs	geen gegevens	geen gegevens
Pak Yu Tam	Joint Company Secretary	2.7yrs	geen gegevens	geen gegevens

4.2yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 2162 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Bo Chen	Executive Chairman & CEO	6.6yrs	CN¥4.79m	geen gegevens
Gang Xu	Senior VP & Executive Director	6.4yrs	CN¥1.61m	geen gegevens
Changyun Wang	Senior VP & Executive Director	3.7yrs	CN¥2.81m	geen gegevens
Qi Chen	Senior VP & Non Executive Director	6.4yrs	CN¥178.00k	geen gegevens
Cheuk Kin Law	Independent Non Executive Director	3.6yrs	CN¥572.00k	geen gegevens
Yang Ke	Independent Non Executive Director	3.6yrs	CN¥476.00k	geen gegevens
Xiao-Fan Wang	Independent Non-Executive Director	3.6yrs	CN¥476.00k	geen gegevens
Yilun Liu	Non Executive Director	3.7yrs	geen gegevens	geen gegevens
Min Chuan Wang	Non Executive Director	3.7yrs	geen gegevens	geen gegevens

3.7yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 2162 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).

Keymed Biosciences Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Keymed Biosciences Inc., Annual General Meeting, Jun 25, 2024

Executive Chairman & CEO recently sold HK$6.1m worth of stock

Less than half of directors are independent

Less than half of directors are independent

Keymed Biosciences Inc. Announces Executive Changes

Recent updates

Health Check: How Prudently Does Keymed Biosciences (HKG:2162) Use Debt?

Keymed Biosciences Inc. Receives Marketing Approval from National Medical Products Administration for the Treatment of Moderate-To-Severe Atopic Dermatis in Adults

First half 2024 earnings released: CN¥1.29 loss per share (vs CN¥0.18 profit in 1H 2023)

Keymed Biosciences Inc. to Report First Half, 2024 Results on Aug 27, 2024

There's Reason For Concern Over Keymed Biosciences Inc.'s (HKG:2162) Massive 28% Price Jump

Keymed Biosciences Inc. Announces Phase III Clinical Trial of Stapokibart Injection for the Treatment of Seasonal Allergic Rhinitis

Full year 2023 earnings: EPS misses analyst expectations

News Flash: 10 Analysts Think Keymed Biosciences Inc. (HKG:2162) Earnings Are Under Threat

Keymed Biosciences Inc. (HKG:2162) Just Reported And Analysts Have Been Cutting Their Estimates

Keymed Biosciences Inc., Annual General Meeting, Jun 25, 2024

Full year 2023 earnings: EPS misses analyst expectations

Keymed Biosciences Inc. to Report Fiscal Year 2023 Results on Mar 26, 2024

New minor risk - Share price stability

Keymed Biosciences Inc. Announces Phase III Clinical Trial of Cm310 for the Treatment of Chronic Rhinosinusitis with Nasal Polyps

Keymed Biosciences Inc. Announces New Drug Application of Stapokibart Injection

A Look At The Intrinsic Value Of Keymed Biosciences Inc. (HKG:2162)

Keymed Biosciences Inc. Announces the Latest Data from a Phase I Clinical Study of CMG901

Keymed Biosciences Inc. Announces CM310 Phase III Clinical Trial Topline Data Accepted for Poster Presentation at the European Academy of Dermatology and Venereology Congress 2023

Now 21% undervalued

Executive Chairman & CEO recently sold HK$6.1m worth of stock

Now 21% undervalued

Analysts Just Made A Noticeable Upgrade To Their Keymed Biosciences Inc. (HKG:2162) Forecasts

Consensus revenue estimates increase by 12%

Now 22% undervalued

First half 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.021 in 1H 2022)

Keymed Biosciences Inc. to Report First Half, 2023 Results on Aug 24, 2023

Consensus EPS estimates fall by 24%

Keymed Biosciences Inc. Announces Latest Data from the Phase I Clinical Study of CM313

Keymed Biosciences Inc. Announces Latest Development on Phase III Clinical Trial of CM310 for the Treatment of Moderate to Severe Atopic Dermatitis in Adults

Consensus EPS estimates upgraded to CN¥1.30 loss

Broker Revenue Forecasts For Keymed Biosciences Inc. (HKG:2162) Are Surging Higher

Keymed Biosciences Inc. Announces Latest Results from the Phase Ia Clinical Study of CMG901 at the 2023 ASCO GI CANCERS SYMPOSIUM

Less than half of directors are independent

Keymed Biosciences Inc. Announces Center for Drug Evaluation of the China National Medical Products Administration Granted CMG901 the Breakthrough Therapy Designation for the Treatment of Advanced Gastric and Gastroesophageal Junction

Keymed Biosciences Inc. Announces Center for Drug Evaluation of the National Medical Products Administration Has Granted CMG90

InnoCare Pharma and Keymed Biosciences Jointly Announce Approval of Clinical Trial of CCR8 Monoclonal Antibody CM369

Keymed Biosciences Inc. to Report First Half, 2022 Results on Aug 29, 2022

Companies Like Keymed Biosciences (HKG:2162) Are In A Position To Invest In Growth

Keymed Biosciences Inc. Receives Grants from Center for Drug Evaluation of the National Medical Products Administration for CM310

Keymed Biosciences Announces Dosing of First Patient in Phase I Trial of Bispecific Antibody CM350

Less than half of directors are independent

U.S. Food and Drug Administration Grants CMG901 Fast Track Designation as Monotherapy for the Treatment of Unresectable or Metastatic Gastric and Gastroesophageal Junction Cancer

Keymed Biosciences Inc. Announces Phase II Clinical Study of its Self-Developed Class1 Innovative Drug CM310 Recombinant Humanized Monoclonal Antibody Injection

Keymed Biosciences Inc. Announces Executive Changes

InnoCare Pharma and Keymed Biosciences Jointly Announce Dosing of First Patient in Clinical Trial of CD20xCD3 Bispecific Antibody CM355

Keymed Biosciences Inc. Announces Positive Results from Cm310 Atopic Dermatitisphase IIB Clinical Study

InnoCare and Keymed Jointly Announce Approval of Clinical Trial of CD20xCD3 Bispecific Antibody CM355

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd